header
Current treatment options lack the efficacy required to adequately manage Generalized Pustular Psoriasis (GPP) flares

UNDERSTANDING
THE UNMET NEEDS IN TREATING GPP1,2

UNMET NEEDS ASSOCIATED WITH GPP

Unmet needs in diagnosis and treatment of GPP:

  • Patients with GPP need fast-acting treatments that completely resolve GPP flares.1-3

  • There is a need for treatment guidelines that are GPP-specific for the treatment of GPP.2,4,5

  • The availability of approved GPP treatments varies by country.2,4,5

Suitcase logo

GPP is a rare disease that physicians seldom treat, which may hinder physician confidence in diagnosis.6,7

Healthcare professional logo

Patients may present in the emergency setting, where there may not be a dermatologist on call.4

Hospital logo

There are currently no diagnostic or prognostic biomarkers for GPP.6

DR STROBER SHARES INFORMATION ON THE UNMET NEED ASSOCIATED WITH GPP1,2

...there is a high unmet need for effective, fast-acting, GPP-specific therapies that completely resolve GPP flares.”
Dr Bruce Strober

DR GOODERHAM DISCUSSES THE UNMET NEED ASSOCIATED WITH GPP1,2

Treatment in clinical practice often follows existing guidance for plaque psoriasis.”
Dr Melinda Gooderham

GPP-SPECIFIC GUIDELINES ARE LACKING2,4,5  

The standard of care for GPP varies across geographies. There is a need for international, evidence-based guidelines for the management of GPP flares.2,4,5

 

DR LANGLEY PROVIDES INSIGHT ON TREATMENT GUIDELINES FOR GPP

Due to the rarity of disease, the guideline recommendations to date are based on very low-quality data.”
Dr Richard Langley

THERE IS A NEED FOR THERAPIES THAT

Tick logo

PROVIDE SUSTAINED DISEASE CONTROL1,2

Logo of a person

REPLACE CURRENT TREATMENT OPTIONS THAT HAVE LIMITED EFFICACY1,2,9

Medal logo

HAVE AN ACCEPTABLE SAFETY PROFILE2,8

Warning logo

RAPIDLY AND EFFECTIVELY RESOLVE GPP FLARES1-3

Ready to test your knowledge of GPP

GPP=Generalized Pustular Psoriasis.

REFERENCES

  1. Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239-252. doi:10.1080/1744666X.2019.1708193

  2. Strober B, Kotowsky N, Medeiros R, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona registry dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529-541. doi:10.1007/s13555-021-00493-0

  3. Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11(3):e043666. doi:10.1136/bmjopen-2020-043666

  4. Strober B, Leman J, Mockenhaupt M, et al. Unmet educational needs and clinical practice gaps in the management of generalized pustular psoriasis: global perspectives from the front line. Dermatol Ther (Heidelb). 2022;12:381-392. doi:10.1007/s13555-021-00661-2

  5. Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131-144. doi:10.2147/PTT.S98954

  6. Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis-a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27(10):1067-1077. doi:10.1111/exd.13699

  7. Reisner DV, Johnsson FD, Kotowsky N, Brunette S, Valdecantos W, Eyerich K. Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23(suppl 1):65-71. doi:10.1007/s40257-021-00663-y

  8. Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235-1270. doi:10.1111/1346-8138.14523

  9. Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011-1017. doi:10.1111/1346-8138.13306